Stockreport

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

BeOne Medicines Ltd. - American Depositary Shares  (ONC) 
PDF Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated [Read more]